September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Intravitreal pirfenidone inhibits post traumatic proliferative vitreoretinopathy
Author Affiliations & Notes
  • Sarbani Hazra
    Veterinary Surgery & Radiology, WBUAFS, Kolkata, India
  • B.N.M Khalida Khatun
    Veterinary Surgery & Radiology, WBUAFS, Kolkata, India
  • Sudip Nandi
    CSIR-IICB, Kolkata, India
  • RAJDEEP GUHA
    CSIR-IICB, Kolkata, India
  • Sushovan Chowdhury
    CSIR-IICB, Kolkata, India
  • Samar Basak
    Disha Eye Hspital, Barrackpore, India
  • Subramanian Krishnakumar
    Sankara Nethralaya, Chennai, India
  • Aditya Konar
    CSIR-IICB, Kolkata, India
  • Footnotes
    Commercial Relationships   Sarbani Hazra, None; B.N.M Khalida Khatun, None; Sudip Nandi, None; RAJDEEP GUHA, None; Sushovan Chowdhury, None; Samar Basak, None; Subramanian Krishnakumar, None; Aditya Konar, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5370. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sarbani Hazra, B.N.M Khalida Khatun, Sudip Nandi, RAJDEEP GUHA, Sushovan Chowdhury, Samar Basak, Subramanian Krishnakumar, Aditya Konar; Intravitreal pirfenidone inhibits post traumatic proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5370.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the efficacy and safety of intravitreal pirfenidone for inhibition of proliferative vitreoretinopathy in a model of penetrating ocular injury.

Methods : Penetrating trauma was induced on the retina of rabbit and treated either with 0.1 ml of PBS or 0.1 ml of 0.5% pirfenidone, and development of PVR was evaluated clinically and graded after one month. Histopathology and immunohistochemistry with α SMA and collagen-1 were performed to validate further the clinical assessment. A similar injury was inflicted in rat eye and treated either with 10 µl of PBS or 10 µl of 0.5% pirfenidone, expression of cytokine at different time points were examined by RT-PCR. Availability of pirfenidone in the vitreous of rat at various time points was determined by HPLC following injection of 10 µl of 0.5% pirfenidone. In normal rabbit eye, 0.1 ml of 0.5% pirfenidone was injected to evaluate any toxic effect.

Results : Prevention of PVR formation was observed clinically in animals injected with pirfenidone, and the animals obtained significantly (p<0.05) lesser PVR grade than the PBS-treated control animals. Pirfenidone inhibited increased expression of cytokines as observed in control eyes. Pirfenidone could be detected up to 96 hrs in the vitreous of rat eye following single intravitreal injection. Pirfenidone did not show any adverse effect following intravitreal injection; eyes were devoid of any abnormal clinical sign, IOP and ERG did not show any significant change and histology of retina remained normal.

Conclusions : Pirfenidone can provide a potential and safe therapy for PVR

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×